1 Japanese Ministry of Health, Labour and Welfare: Vital Statistics Japan, Cancer Registry and Statistics. Cancer Information Service, National Cancer Center, Japan. Cancer Mortality, 2019. Available at: http://www.ganjoho.jp/reg_stat/statistics/dl/ index ・html#mortality [Last accessed on June 7, 2021]
2 Strobel O, Neoptolemos J, Jager D and Biichler MW: Optimizing the outcomes of pancreatic cancer surgery. Nat Rev Clin Oncol 16(J): 11-26, 2019. PMID: 30341417. DOI: 10.1038/s41571・018・0112・1
3 Burris HA 3rd,Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC,Portenoy RK, Storniolo AM, Tarassoff P, Nelson R,Dorr FA, Stephens CD and Von Hoff DD: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.J Clin Oncol 15(6): 2403-2413, 1997. PMID: 9196156. DOI:10.1200/JCO.l997.15.6.2403
4 Conroy T,Desseigne F,Ychou M, Bouchd O,Guimbaud R, Bdcouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de la Fouchardifere C, Bennouna J, Bachet JB, Khemissa-Akouz F, Ρέτέ- Verg6 D,Delbaldo C,Assenat E, Chauffert B, Michel P, Montoto- Grillot C,Ducreux M, Groupe IXimeurs Digestives of Unicancen and PRODIGE Intergroup: FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364(19):1817.1825, 2011.PMID: 21561347.DOI:10.1056/NEJMoalOl 1923
5 Okusaka T, Ikeda M, Fukutomi A, Ioka T,Furuse J,Ohkawa S, Isayama H and Boku N: Phase II study of FOLFIRINOX for chemotherapy-naive Japanese patients with metastatic pancreatic cancer. Cancer Sci 105(10): 1321-1326, 2014. PMID: 25117729· DOI:104111/casJ2501
6 Li X, Ma T, Zhang Q, Chen YG,Guo CX, Shen YN, Sun PW, Li GG, Gao SL, Que RS, Lou JY,Yu RS,Yuan Y,Wei QC,Wei SM, Zhang Y, Zheng L, Bai XL and Liang TB: Modified- FOLFIRINOX in metastatic pancreatic cancer: A prospective study in Chinese population. Cancer Lett 406: 22-26, 2017. PMID: 28729048. DOI:10.1016/j.canlet.2017.07.012
7 Yoshida K,Iwashita T,Uemura S,Maruta A, Okuno M, Ando N, Iwata K, Kawaguchi J,Mukai T and Shimizu M: A multicenter prospective phase II study of first-line modified FOLFIRINOX for unresectable advanced pancreatic cancer. Oncotarget 8(67): Π1346-111355, 2017. PMID: 29340058. DOI: 10.18632/oncotarget.22795
8 Stein SM, James ES, Deng Y,Cong X,Kortmansky JS, Li J, Staugaard C, Indukala D, Boustani AM, Patel V,Cha CH, Salem RR, Chang B, Hochster HS and Lacy J: Final analysis of a phase II study of modified FOLFIRINOX in locally advanced and metastatic pancreatic cancer. Br J Cancer 114(7): 737-743, 2016. PMID: 27022826. DOI:10.1038/bjc.2016.45
9 Ghorani E, Wong HH,Hewitt C, Calder J,Corrie P and Basu B: Safety and efficacy of modified FOLFIRINOX for advanced pancreatic adenocarcinoma: A UK single-centre experience. Oncology 89(5): 281-287, 2015. PMID: 26372卯5. DOI: 10.1159/000439171
10 Ozaka M, Ishii H, Sato T, Ueno M, Ikeda M, Uesugi K, Sata N, Miyashita K, Mizuno N,Tsuji K, Okusaka T and Furuse J: A phase II study of modified FOLFIRINOX for chemotherapy- na'ive patients with metastatic pancreatic cancer. Cancer Chemother Pharmacol 81(6):1017-1023, 2018. PMID: 29633005. DOI: 10J007/s00280-018-3577-9
11 Mahaseth H, Brutcher E, Kauh J, Hawk N, Kim S, Chen Z, Kooby DA, Maithel SK, Landry J and El-Rayes BF: Modified FOLFIRINOX regimen with improved safety and maintained efficacy in pancreatic adenocarcinoma. Pancreas 42(8): 1311-1315, 2013. PMID: 24152956. DOI:10.1097/MPAOb013e31829e2006
12 Nelson RS, Seligson ND, Bottiglieri S, Carballido E, Cueto AD, Imanirad I, Levine R, Parker AS, Swain SM, Tillman EM and Hicks JK: UGT1A1 guided cancer therapy: Review of the evidence and considerations for clinical implementation. Cancers (Basel) 13(7):1566, 2021,PMID: 33805415. DOI:103390/cancers 13071566
論文の公開元へ
